DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Arrowhead Pharma Reports Initiation Of Phase 1/2 Study Of ARO-HSD In Normal Healthy Volunteers, Patients with NASH, Suspected NASH

Benzinga · 03/03/2020 12:31